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Interrelationships between serum levels of 
amiodarone, desethylamiodarone, reverse T3 
and the QT interval during long-term 
amiodarone treatment 
The interrelationships between serum levels of amiodarone, desethylamiodarone, and reverse Tar 
and changes in the corrected QT interval (AQT,) were examined in 22 patients during long-term 
treatment with amiodarone. At 1, 3, and 6 months of follow-up, the correlation coefficient 
between serum levels of amiodarone or desethylamiodarone and reverse T3 ranged from 0.01 to 
-0.2 (p > 0.4). At the same time intervals, the correlation coefficient between both amiodarone 
and desethylamiodarone levels and AQT, ranged from 0.1 to -0.1 (p > 0.6), and the correlation 
coefficient between reverse T3 and AQT, also ranged between 0.1 to -0.1 (p > 0.5). Substituting 
percent AQT. for AQT, also did not reveal a significant correlation. These data demonstrate that 
serum levels of reverse T3 cannot be used as a substitute for serum levels of amiodarone in 
monitoring patients being treated with amiodarone. The absence of a correlation between serum 
reverse T, levels and AQT, suggests that the delay in repolarization which occurs during 
amiodarone therapy is not secondary to an amiodarone-induced abnormality in thyroid hormone 
metabolism. (AM HEART J 111:644, 1986.) 
Jeffrey M. Baerman, M.D., Thomas Annesley, Ph.D., Lorenzo A. DiCarlo, Jr., M.D., 
Mary Kay Foley, R.N., John M. Nicklas, M.D., Barry J. Crevey, M.D., and 
Fred Morady, M.D. Ann Arbor, Mich. 
Amiodarone blocks the peripheral conversion of 
thyroxine (T4) to tri-iodothyronine (T,),’ resulting in 
increased production of reverse T,. Some investiga- 
tors2z3 have reported that the increase in the serum 
reverse T, level which occurs during chronic amioda- 
rone therapy correlates with amiodarone’s antiar- 
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rhythmic action. These investigators have suggested 
that the serum level of reverse T, may be helpful in 
monitoring long-term amiodarone therapy. 
Other investigators have demonstrated that amio- 
darone’s antiarrhythmic effect correlates with the 
serum amiodarone leve1.4-6 Therefore, as is the case 
with serum levels of reverse T3, serum levels of 
amiodarone have also been reported as being useful 
in monitoring amiodarone’s efficacy and toxicity. 
However, the relationship between serum levels of 
reverse T, and serum levels of amiodarone, or its 
principal metabolite, desethylamiodarone, has not 
been reported upon to date. 
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Fig. 1. Relationship between serum amiodarone levels and reverse T, (RT,) levels at 1,3, and 6 months 
of treatment. Correlation coefficients and p values are as shown. 
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Fig. 2. Relationship between serum desethylamiodarone levels and reverse T3 (RT,) levels at 1, 3, and 6 
months of treatment. Correlation coefficients and p values are as shown. 
The purpose of this study was to determine 
whether any relationship exists between serum lev- 
els of reverse T, and amiodarone or desethylamioda- 
rone during chronic amiodarone therapy. Because 
either serum reverse T, or serum amiodarone levels 
may be more conveniently obtained in a particular 
hospital or community, it would be useful to know if 
these serum levels can be used interchangeably in 
following patients being treated with amiodarone. 
Also examined was the relationship between serum 
levels of reverse T,, amiodarone, and desethylamio- 
darone, and an index of amiodarone’s cardiac tissue 
effect, namely prolongation of the QT interval. 
METHODS 
This study was conducted in 22 patients who were 
treated with amiodarone for a period of at least 6 months. 
All patients had normal baseline thyroid function and no 
clinical evidence of renal or hepatic dysfunction. There 
were 18 men and 4 women, and their mean age was 
53 2 17 years (mean 5 standard deviation). Coronary 
artery disease was present in 11 patients, valvular heart 
disease was found in three, and idiopathic dilated cardio- 
myopathy was seen in one, whereas four patients had no 
identifiable structural heart disease. The indication for 
amiodarone therapy in these patients was ventricular 
tachycardia refractory to conventional antiarrhythmic 
drugs in 18 patients, and atria1 fibrillation or flutter in 
four patients. 
Before the initiation of therapy with amiodarone, an 
ECG was obtained at least four half-lives after discontinu- 
ation of all antiarrhythmic drugs, as were baseline blood 
samples for determination of the serum levels of reverse 
TB, amiodarone, and desethylamiodarone. Amiodarone 
therapy was initiated at a dose of 1200 mg/day for 1 week, 
followed by 800 mg/day for 1 month, then 600 mg/day for 
1 month; the chronic maintenance dose was 200 to 400 
mg/day. An ECG and blood s’amples for determination of 
the serum levels of amiodarone, desethylamiodarone, and 
reverse T, were obtained after 1, 3, and 6 months of 
treatment. 
The QT interval was measured from the ECG lead in 
which termination of the T wave was best defined. The 
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Fig. 3. Relationship between serum reverse T3 levels and AQT, at 1, 3, and 6 months of treatment. 
Correlation coefficients and p values are as shown. 
Fig. 4. Relationship between serum amiodarone levels and AQT, at the regular follow-up intervals. 
Correlation coefficients and p values are as shown. 
same ECG level was used for all QT measurements in each 
patient. The QT intervals were measured independently 
by two observers blinded to the serum levels of reverse T, 
and amiodarone. If the QT measurement differed by more 
than 0.02 second, differences were resolved by common 
agreement. The corrected QT interval (QT,) was calcu- 
lated with Bazett’s formu1a.7 
Serum levels of reverse T3 were determined by radioim- 
munoassay. Serum levels of atniodarone and desethylam- 
iodarone were determined with the extraction technique 
of Storey et al.,8 and the chromatographic conditions of 
Flanagan et a1.9 
Correlation coefficients were determined with a linear 
regression model. p values of < 0.05 were considered 
significant. 
RESULTS 
There was not a significant correlation between 
serum levels of amiodarone or desethylamiodarone 
and reverse T3 after either 1, 3, or 6 months of 
treatment with amiodarone (Figs. 1 and 2). There 
was not a significant correlation between serum 
levels of reverse T, and AQT, after either 1, 3, or 6 
months of treatment with amiodarone (Fig. 3). Also, 
there was not a significant correlation between 
serum levels of amiodarone or desethylamiodarone 
and AQTC at any of the follow-up intervals (Figs. 4 
and 5). Expressing AQT, in terms of percent change 
resulted in no improvement in the above correla- 
tions. 
DISCUSSION 
The results of this study demonstrate that neither 
serum levels of amiodarone nor desethylamiodarone 
correlate with the serum level of reverse T, during 
long-term amiodarone therapy. Therefore, serum 
levels of reverse T, cannot be used as a substitute for 
serum levels of amiodarone in monitoring patients 
being treated with amiodarone (Fig. 6). 
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Fig. 5. Relationship between serum desethylamiodarone levels and AQT, at the regular follow-up 
intervals. Correlation coefficients and p values are as shown. 
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Fig. 6. QT,, together with serum levels of reverse T, and amiodarone, are demonstrated for an individual 
patient on long-term amiodarone therapy for ventricular tachycardia. Note the discordant trends in all 
three variables. 
Also of note is the finding that the serum level of 
reverse T, did not correlate with the degree of 
amiodarone-induced delay in repolarization, as mea- 
sured by prolongation of the QT interval. Some 
investigators have suggested that amiodarone’s 
mechanism of action may involve the induction of a 
local hypothyroid state in cardiac muscle.2,3 Howev- 
er, the lack of correlation between changes in the QT 
interval and reverse T, during treatment with amio- 
darone suggests that the delay in repolarization 
which occurs with amiodarone is not secondary to an 
abnormality in thyroid hormone metabolism. Of 
note is that iopanoic acid, which has effects on 
thyroid hormone metabolism similar to amiodarone, 
has been shown to be without ant&rhythmic 
effects.‘O 
Serum amiodarone or desethylamiodarone levels 
also did not correlate with changes in the QT 
interval during long-term treatment with amioda- 
rone. It is unknown whether tissue levels of amioda- 
rone or its metabolite might correlate to a better 
degree with changes in the QT interval. 
This study has several limitations. Firstly, blood 
samples were drawn at the time of outpatient visits 
at a variable number of hours after the last dose of 
amiodarone. However, it is unlikely that this factor 
significantly affected the results of this study, 
because Haffajee et al.* reported that there are only 
minor fluctuations in the serum amiodarone level in 
the 24-hour dosing interval during maintenance 
amiodarone therapy. Second, because myocardial 
tissue levels of amiodarone or desethylamiodarone 
were not measured, it is unknown whether tissue 
levels of amiodarone or its metabolite correlate with 
changes in the QT interval. Third, we were unable to 
correlate serum drug or reverse T, levels with amio- 
darone’s antiarrhythmic efficacy; the majority of 
patients in this study had infrequent and sporadic 
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arrhythmias, and antiarrhythmic efficacy could not 
be adequately assessed over a 6-month follow-up 
period. 
We gratefully acknowledge the excellent secretarial assistance 
of Mrs. Lisa Hackbarth. 
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Lorcainide therapy in a cardiac arrest 
population 
Thirty-eight patients with a prior history of cardiac arrest underwent programmed electrical 
stimulation (PES) studies and serial drug testing. Lorcainide was tested acutely in all 38 patients 
and prevented ventricular tachycardia (VT) or ventricular fibrillation (VF) induction in 14 patients 
and failed in 24 (efficacy rate 37%). Procainamide had failed clinically (cardiac arrest or 
breakthrough VT) in 16 patients, seven patients had previously severe adverse side effects, and 
thus only 15 were tested on procainamide at PES testing with seven protected. Following initial 
studies, 14 patients were started on lorcainide oral therapy and 24 on other therapy determined 
effective at PES testing (N-acetylprocainamide-two, flecainide-nine, bethanidine-three, 
slow-release procainamide hydrochloride-three, quinidine-two, cibenzoline-one, amiodarone-four). 
After 29 f 7 months follow-up, three are alive on lorcainide therapy, five discontinued therapy 
due to side effects; six died-three sudden deaths (33%) and two cardiac deaths (both 
myocardial infarctions). Twenty out of 24 patients are alive who were started on PES predicted 
effective therapy other than lorcainide; four died -three sudden deaths (13%) and one cardiac 
nonsudden death. Antiarrhythmic therapy guided by PES studies gives overall encouraging 
results in a cardiac arrest group of patients. Lorcainide, however, is not tolerated well and 
affords less protection against a sudden death recurrence than is noted in a population on other 
antiarrhythmic therapy predicted effective at PES testing. (AM HEART J 111:648, 1986.) 
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Patients with a prior history of a cardiac arrest are 
among the most electrically unstable, with a high 
incidence of recurrence. They have identified them- 
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